Humacyte, Inc.
ATEV
dialysis access
Resolved
27days ago
Phase 3 readout · Jun 10, 2026
What's at stake
Phase 3 trial results for ATEV in dialysis access are due Jun 10, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced positive top-line interim results for the V012 Phase 3 stu”